Keyword Analysis & Research: bioprosthetic valve stenosis guidelines

ahajournals.org

https://www.ahajournals.org/doi/10.1161/CIR.0000000000000923

WEBDec 17, 2020 · Bioprosthetic valve dysfunction may occur because of either degeneration of the valve leaflets or valve thrombosis. Catheter-based treatment for prosthetic valve dysfunction is reasonable in selected patients for bioprosthetic leaflet degeneration or paravalvular leak in the absence of active infection.

DA: 48 PA: 69 MOZ Rank: 65

asecho.org

https://www.asecho.org/wp-content/uploads/2014/05/2009_Evaluation-of-Prosthetic-Valves.pdf

WEBThis document offers a review of echocardiographic and Doppler techniques used in the assessment of prosthetic valves and provides recommendations and general guidelines for the evaluation of prosthetic valve function on the basis of the scientific literature and the consensus of an inter-national panel of experts.

DA: 60 PA: 30 MOZ Rank: 7

asecho.org

https://www.asecho.org/guideline/recommendations-for-evaluation-of-prosthetic-valves-with-two-dimensional-and-doppler-echocardiography/

WEBIn general, evaluation of prosthetic valve function is more challenging, on the basis of the variability of inherent mild obstruction observed with the wide range of prosthetic valve types and sizes. Thus, the cardiac history plays a major role in the echocardiographic evaluation by documenting the type and size of the inserted valve or conduit.

DA: 30 PA: 32 MOZ Rank: 50

ahajournals.org

https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000932

WEBsevere aortic stenosis should be a shared decision-making process that considers the lifetime risks and benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (trans-catheter versus surgical). 7. Indications for intervention for valvular regurgi-tation are relief of symptoms and prevention of

DA: 42 PA: 73 MOZ Rank: 64

jacc.org

https://www.jacc.org/doi/10.1016/j.jacc.2020.11.035

WEB2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Journal of the American College of Cardiology. JACC Journals › JACC › Archives › Vol. 77 No. 4. Previous Next.

DA: 57 PA: 41 MOZ Rank: 16

acc.org

https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2020/12/16/22/01/2020-ACC-AHA-VHD-GL-Pt-3-GL-VHD

WEBDec 17, 2020 · Bioprosthetic SAVR or mitral valve replacement: Anticoagulation with VKA to an INR of 2.5 is reasonable for 3-6 months postoperatively (Class 2b). Mechanical valve prosthesis: The use of direct thrombin inhibitors (dabigatran) or anti-Xa direct oral anticoagulants remains a Class 3 contraindication.

DA: 34 PA: 14 MOZ Rank: 75

ahajournals.org

https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000923

WEBbicuspid aortic valve cardiac surgery guidelines infective endocarditis mitral regurgitation mitral stenosis mitral transcatheter edge-to-edge repair prosthetic valve pulmonic regurgitation pulmonic stenosis transcatheter aortic valve replacement or implantation tricuspid regurgitation tricuspid stenosis valvular heart disease

DA: 69 PA: 37 MOZ Rank: 66

jtcvs.org

https://www.jtcvs.org/article/S0022-5223(21)00592-4/fulltext

WEBBioprosthetic valve dysfunction may occur because of either degeneration of the valve leaflets or valve thrombosis. Catheter-based treatment for prosthetic valve dysfunction is reasonable in selected patients for bioprosthetic leaflet degeneration or paravalvular leak in the absence of active infection.

DA: 65 PA: 72 MOZ Rank: 1

jacc.org

https://www.jacc.org/doi/10.1016/j.jacc.2020.11.018

WEBFor patients with AF and native valve heart disease (except rheumatic mitral stenosis [MS]) or who received a bioprosthetic valve >3 months ago, a non–vitamin K oral anticoagulant (NOAC) is an effective alternative to VKA anticoagulation and should be administered on the basis of the patient’s CHA 2 DS 2-VASc score (1,2).

DA: 6 PA: 24 MOZ Rank: 13

acc.org

https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/03/14/18/26/2017-aha-acc-focused-update-of-valvular-heart-disease

WEBMar 15, 2017 · A TAVR valve-in-valve procedure is reasonable among severely symptomatic patients with bioprosthetic aortic valve stenosis who are assessed by the heart valve team to be at high or prohibitive surgical risk (Class IIa, LOE B-NR). Prosthetic valve regurgitation:

DA: 21 PA: 10 MOZ Rank: 26

microsoft.com

http://go.microsoft.com/fwlink/?LinkID=617350

DA: 12 PA: 17 MOZ Rank: 96